+180.0%
HIMS vs MRNA
+730.5%
-550.5%
-87.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.6% | +0.7% | -2.4% | -1.8% |
| 7D | -1.4% | -8.2% | +6.9% | -0.1% |
| 30D | -10.1% | +125.6% | -135.6% | -29.4% |
| 3M | -1.2% | +197.1% | -198.3% | -26.7% |
| 6M | +16.9% | +148.5% | -131.6% | -10.1% |
| YTD | -15.5% | +363.3% | -378.8% | -42.6% |
| 1Y | -42.6% | +462.0% | -504.6% | -62.6% |
| 3Y | +320.2% | +26.9% | +293.3% | +239.0% |
| 5Y | +215.0% | -69.6% | +284.6% | +183.7% |
| All | +180.0% | +730.5% | -550.5% | +139.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling